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Abstract: Both Human Immunodeficiency Virus (HIV) infection and AIDS remain major 
  public health crises in Nigeria, a country which harbors more people living with HIV/AIDS than 
any country in the world, with the exception of South Africa and India. In response to the HIV 
pandemic, global and international health initiatives have targeted several countries, including 
Nigeria, for the expansion of antiretroviral therapy (ART) programs for the increasing number 
of affected patients. The success of these expanded ART initiatives depends on the treated 
individual’s continual adherence to antiretroviral (ARV) drugs. Thirteen peer-reviewed studies 
concerning adherence to ART in Nigeria were reviewed with very few pediatric and adolescent 
studies being found. Methodologies of adherence measurement were analyzed and reasons for 
nonadherence were identified in the geopolitical zones in the federal republic of Nigeria. The 
results of the literature review indicate that adherence to ART is mixed (both high and low 
adherence) with patient self-recall identified as the common method of assessment. The most 
common reasons identified for patient nonadherence include the cost of therapy (even when 
the drugs are heavily subsidized), medication side effects, nonavailability of ARV drugs, and 
the stigma of taking the drugs. This manuscript highlights the policy and practice implications 
from these studies and provides recommendations for future ART program management.
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Introduction
The human immunodeficiency virus (HIV) pandemic continues to spread in the popula-
tion making HIV disease one of the most important public health crises in the world. 
In 2007, there were approximately 33 million people globally living with HIV , with 
two million deaths attributed to HIV/AIDS and three million new infections occur-
ring annually.1 Sub-Saharan Africa harbors about 67% of the total worldwide infected 
population with Nigeria having the third largest infected population (2 to 3.2 million) of 
people living with HIV/AIDS (PLWHA) in the world after South Africa and India.1
Global health initiatives such as the United States (US) President’s Emergency 
Program for AIDS Relief (PEPFAR) and the Global Fund to fight AIDS, Tuberculosis 
and Malaria (GFTAM) have responded to the HIV pandemic by expanding the 
  provision of ART to the increasing number of affected patients.1 This has resulted in 
the expansion of treatment and prevention programs that have increased ART access 
to previously un-served and underserved populations. Nigeria is one of the target 
  countries for these international programs and is also a country with strong local 
political support for these initiatives.HIV/AIDS - Research and Palliative Care 2010:2 70
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Antiretroviral (ARV) drugs have to be taken as a lifelong 
therapy and their success relies on continual adherence to the 
medication regimen. A rate of adherence of approximately 
90%–95% is required to avoid rapid development of 
drug resistance and treatment failure.2,3 Large scale 
  adherence studies have been conducted in African countries 
  demonstrating mixed results on patient faithfulness to ART.4 
With the rapid increase in patient access to ART in Nigeria, 
it has become vital to continuously monitor treatment 
adherence and identify interventions that can encourage its 
sustainability.
This retrospective literature review specifically focuses 
on patient adherence to ART from the beginning of Nigeria’s 
ART program in 2002 to the end of November 2009. 
Results from research studies specifically measuring patient 
  adherence to highly active ARV drugs are summarized and 
possible structural, sociocultural and/or economic problems, 
as well as other factors that may have affected ART adherence 
in Nigeria, are identified. In addition, certain issues regarding 
ART programs which are specific to Nigeria and should be 
taken into consideration when modifying these programs’ 
policies and practice are also identified.
Adherence to combination  
antiretroviral therapy
Treatment adherence is defined as the extent to which a 
person currently takes prescribed medication. It is widely 
agreed that in order to achieve an undetectable viral load 
and prevent the development of drug resistance, a person 
on ARV drugs needs to take at least 95% of the prescribed 
doses on time.5
There is no gold standard to measure adherence. 
  Commonly used methods include patient self-report, pill 
counts, pharmacy refill records, drug level monitoring, 
electronic drug monitoring, and physician assessment, each 
of which has advantages and disadvantages.4 The most 
  commonly used method in resource-limited settings is self-
report or pharmacy refill records.5
Adherence has been shown to be a major predictor of viral 
suppression of HIV replication,6 emergence of ART drug 
resistance,7 disease progressions,8 and death.9,10 Adherence 
monitoring and evaluation of ART are, therefore, essential 
public health surveillance tools in the prevention of HIV in 
high, middle, and low income countries.
Barriers to adherence
Systematic reviews11,12 have indicated that the most important 
and frequent factors that negatively impact adherence 
in developing countries are cost, stigma, alcohol abuse, 
and structural barriers such as lack of transportation and 
  pharmacy stock-outs.
An analysis of the barriers that affect adherence should 
be viewed as a dynamic interaction of biologic and social 
factors.13 The main biosocial variables needed to understand 
nonadherence can be defined within eight categories: 
  socioeconomic factors, health care system factors, social 
capital, cultural methods of health and disease, personal 
characteristics, psychological factors, clinical factors, and 
antiretroviral regimen.13 Based on this framework, addressing 
adherence may require providing social support to patients, 
lowering or eliminating user fees, bringing health care 
workers closer to the patients, improving drug procurement 
strategies and/or creating mechanisms for lowering the cost 
of drugs and laboratory tests.13
In other settings, addressing adherence may require 
investing in and improving primary health care, public 
  hospital and referral networks or recruiting and retaining 
human resources.13 An understanding of the complex 
  interplay of the biosocial factors is necessary to understand 
nonadherence, which can help in guiding the designs of more 
effective nonadherence intervention programs.13
The Nigerian ART program
The Federal Government of Nigeria initiated the national 
ARV program in January 2002 as part of an expanded 
response to care and support for PLWHA. Under this 
  program, 10,000 adults and 5000 children were treated with a 
3-drug ARV combination; 2 NRTI (lamivudine + stavudine) 
and 1 NNRT (nevirapine). The program began in February 
2002 involving 25 treatment centers across the 6 geopolitical 
zones of the country and was subsidized at a cost of US$ 10 
a month for each patient.14
Unfortunately, in 2004 the program suffered a major 
setback when it was hit by a shortage of the US$ 3.5 million 
worth of drugs imported from India. During this time, many 
patients were off drugs for up to 3 months, which created a 
structurally-induced nonadherence problem in the national 
ARV drug program. Eventually, the program was resumed 
when another US$ 3.8 million worth of drugs was ordered 
and received.
Another program was started in 2006 with the goal of pro-
viding ARV drugs at no cost to about 250,000 HIV-positive 
patients. Although a total of 74 treatment sites were par-
ticipating in this program by the end of 2006,15 only about 
15% of PLWHA needing ARV drugs in Nigeria had access 
to this treatment.16HIV/AIDS - Research and Palliative Care 2010:2 71
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Materials and methods
An electronic search of published literature was conducted 
using the search terms ‘adherence’, ‘antiretroviral therapy’, 
and ‘Nigeria’. PubMed®, ISI Web of Science® Science 
Citation Index®, PloS Medicine, and all indexed journals 
on HIV/AIDS that addressed adherence to ART in Nigeria 
from 2002 to 2009 were searched. Websites of international 
organizations, international conferences on all aspects of 
HIV/AIDS, and private research HIV/AIDS foundations 
were also explored and an Internet Google® search using the 
same terms was also completed. A total of twenty one articles 
addressing adherence to ART in Nigeria were identified. 
Thirteen peer-reviewed articles were included in this review 
and eight conference abstracts were excluded. The search 
was restricted to English language articles only.
Results
A summary of the thirteen identified research studies 
  measuring adherence to ART in Nigeria is shown in Table 1. 
All the data collected for these studies came from HIV patients 
who were receiving ARV drugs through international initia-
tives as well as the national government program. The Table 
includes the health facility and the geopolitical zone where 
each study was conducted, the method of adherence assess-
ment and measurement, and the reasons for nonadherence.
Study characteristics and  
adherence measurements
Study characteristics concerning adherence to treat-
ment showed mixed results with some showing low 
adherence14,17,18,20–23,25,26 and others showing high adher-
ence.19,22,24,27,28 One study19 used direct observation of ART 
using both community providers and family members and 
compared adherence with those patients who self-adminis-
tered their drugs. Only one pediatric adherence study was 
indentified.24 All other study populations were adult HIV 
patients within the age range of 35–40 years. One study22 
compared adherence in fasting and nonfasting HIV patients 
during the Ramadan period. Only one study17 utilized the 
services of community health extension workers to follow-
up on patients who missed monthly clinic appointments. 
Another study20 incorporated focus group discussions and 
ethnographic analysis to compare adherence from two treat-
ment centers and to show how cost-of-treatment could be a 
determinant factor in adherence.
All of the studies reviewed used patient self-recall to 
assess adherence. Two studies18,23 combined patient recall 
with the pharmacy refill method and in three studies14,19,22 
patient recall was matched with estimation of biologic 
  markers, viral load, and CD4 cell count. These matched 
studies showed that the biologic markers correlated well with 
adherence, increased CD4 cell count, and reduced viral load 
in patients with 95% adherence to ART.
Reasons for nonadherence
Cost to the patient for medication, adverse side effects, 
  nonavailability of drugs, and social stigma were the major 
reasons reported for patient nonadherence and were common 
to all studies reviewed. Forgetfulness on the part of the 
patient and in the case of children (mothers or caregivers) 
was a recurring reason for noncompliance. In addition, pill 
  overload was also mentioned as a factor affecting adherence 
in two of the studies.21,25 The study that utilized directly 
observed treatment methodology using community sup-
port showed a much greater adherence rate when compared 
to those studies where patients administered their own 
  medications.19
Discussion
The level of adherence to drug therapy has been reported to 
affect the outcome of treatment in the patients on ARV drugs. 
While good adherence results are effective in reducing viral 
loads and restoring a patient’s immune system, nonadherence 
often leads to treatment failure.6–9 Studies conducted in 
both developed and developing countries11,12 have shown 
that adherence in developing countries is often equal to or 
higher than that in developed countries,11,12,29 but there is now 
research evidence that this may wane over time.29 The reason 
for these better adherence outcomes in sub-Saharan Africa 
has been attributed to the phenomenon of social capital.30
Patient self-report was the most commonly method of 
adherence measurement used in the studies. This method has 
proven reliable since the estimation of CD4 count and viral 
load in some of the studies14 correlated well with the high 
adherence to drug therapy achieved. Drug level monitoring 
and electronic drug monitoring methods of measurement 
are not commonly used in adherence studies in developing 
countries because they are expensive, technically difficult, 
and require laboratory testing and training of personnel. Even 
studies in advanced countries in North America and Europe 
where these methods are utilized more often, studies still 
show a large dependence on patient self-recall.4
The most prevalent factor and major barrier to adherence 
in all of the studies examined was cost. Although the ARV 
drugs are heavily subsidized in the Nigerian program, patients 
have to bear the cost of transportation to and from the health HIV/AIDS - Research and Palliative Care 2010:2 72
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facility as well as the cost of laboratory testing, which can be 
a huge burden on very poor patients. Therefore poverty is a 
strong determinant of nonadherence although several specific 
factors that interplay with poverty may also contribute to poor 
adherence. For instance, in conflict settings where poverty 
abounds, studies have shown high adherence to ART,31,32 
which emphasizes the role of other factors for nonadherence 
in poverty situations.
The Nigerian national ART program suffered setbacks 
in 2004 and 2005 due to a shortage of ARV drugs and many 
patients did not receive their drugs during that period. This 
structural problem accounted for many cases of nonadherence 
and patients’ dampened morale. This may explain why 
availability of ARV drugs and pharmacy stock-out were 
significant reasons for nonadherence in all studies. In addi-
tion, this system-induced nonadherence could have promoted 
the development of drug resistant strains resulting in the 
worsening of patients’ health and the transmission of drug 
resistant strains in the population.
Globally, stigma and discrimination are major obstacles 
leading to reduced treatment-seeking behavior33 and effective 
HIV/AIDS prevention and care,34 especially in sub-Saharan 
Africa. Studies show that patients often missed their doses 
as a result of fear of being identified as HIV-positive and 
being on ARV medications for the rest of their lives. As a 
result, strategies to address the problem of stigma should 
be important and necessary components of all adherence-
reduction interventions.
Adverse effects of medication and pill burden were also 
identified as pertinent reasons for nonadherence in these 
studies. Interestingly, this issue of side effects with ARV 
drugs was also an important aspect of adherence studies in 
developed countries.11 The adverse effects and pill burden of 
ARV drugs can compromise the effectiveness of treatment 
programs, particularly in low and medium income coun-
tries.35 Therefore, it is important that health care personnel 
engage in adequate patient counseling about these side effects 
and their routine management when they do occur. Pill bur-
den can be particularly difficult, especially for less-educated 
patients. This population may find it difficult to comply with 
the complex treatment regimen with the resultant forgetful-
ness leading to nonadherence. In addition, the modification of 
the treatment regime in predominantly Muslim communities 
in Nigeria to accommodate changes in eating habits during 
the Ramadan fasting period was an important innovation in 
the study by Habib and colleagues.22
The introduction of directly observed therapy for 
  antiretroviral therapy (DOT-ART) currently used in 
  tuberculosis programs, has been shown to be acceptable 
and was associated with good clinical outcome in Haiti.36 
  However, DOT-ART is still controversial because it may 
not be suitable for life-long combination ART37 and there 
are mixed results; some studies did not confer significant 
increases in adherence over self-administered studies.38–40 
Nevertheless, the one DOT-ART study included in this 
review19 did show a significantly higher adherence rate in 
the directly observed patients than in the self administered 
patients.
The effects of sociodemographic factors on adherence 
have also been analyzed. Some studies have found 
  associations between increased adherence rates and patients 
who are older, male and/or have a higher income.11,12 By 
contrast, others have found no such associations.11,12 This 
points to a need for more specific studies on the role of 
sociodemographic factors, particularly educational status, 
gender and income as they affect adherence in low and 
middle income countries.
The findings in this review have important implications 
for government policy and for clinicians. First, the high levels 
of adherence observed in many of the studies in this review 
and in other studies done in sub-Saharan Africa should be 
a call to focus on the maintenance of these high rates. This 
should be done by increasing access to affordable ART and 
establishing both a reliable drug supply and distribution 
network from the pharmacy to the patient. The ‘out-of-stock 
syndrome’ issue as it occurred in 2004 and 2005 should never 
repeat itself. Second, poverty, political conflict, and other 
biosocial factors that may affect adherence should not be used 
as a rationale for delaying the expansion of ART in Nigeria. 
Rather the ART programs should focus on evidence-based 
research to eliminate the barriers of nonadherence in the 
different geopolitical zones of the country with their unique 
characteristics of culture, religion, educational status, and 
health-seeking behaviors.
The clinicians involved in HIV/AIDS care in Nigeria 
need to be better educated about the biosocial factors of 
adherence, the relevance of drug monitoring, viral load, 
CD4 level estimation, as well as other biological markers 
that are necessary for positive patient treatment outcomes. 
Severe weaknesses in the overall drug and biologic markers 
  assessments across various ART centers in Nigeria were 
revealed in the ART program evaluation done by Ekong and 
colleagues.41 In addition, patient counseling on drug regimen, 
side effects, and the recognition of the early signs of adverse 
reactions by patients should be part of the duties of all health 
care personnel involved in these programs. Likewise, adequate HIV/AIDS - Research and Palliative Care 2010:2 75
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management of these drug complications by clinicians should 
be a part of their continuing education.
Conclusions
Relevant adherence research studies in Nigeria have been 
identified and the paucity of pediatric and adolescent 
  adherence studies has been noted. Since Nigeria has a high 
percentage of PLWHA in the world and HIV/AIDS is now a 
significant cause of morbidity and mortality in Nigeria, it is 
imperative that the Nigerian ART program be strengthened. 
This can be done with better management, increased access 
to free or heavily subsidized ARV drugs, more evidenced-
based research into the biosocial factors affecting adherence 
to ART, and the implementation of continuous monitoring 
and evaluation mechanisms for adherence which hold the 
key to the success of the ART program and the prevention 
of treatment failures.
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